/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

subsidiaries as follows: The Company and Subsidiaries Operating Performance of 3rd Quarter Ending September 30th, 2019 Revenues from Sales and Services In Q3 2019, the Company and subsidiaries generated revenues

. The operating results of the Company and its subsidiaries continued to improve, with total revenue and profit at baht 67,423.88 million and baht 6,176.59 million respectively, an increase of 2.08% and

6.01 Total Revenues 298.26 604.18 1,018.60 1,620.84 797.50 Costs 203.56 321.20 580.70 856.82 380.02 Selling And Administrative Expenses 82.93 57.10 126.84 433.21 329.69 Total Cost And Expenses 287.42

673.64 664.13 793.69 Other Income 26.64 169.36 185.43 19.16 40.60 Total Revenues 368.02 493.19 860.62 683.30 836.16 Costs 208.19 203.39 406.29 415.60 542.68 Selling And Administrative Expenses 103.78

Consolidate Consolidate Consolidate Revenue From Operations 93.77 253.84 394.87 857.61 457.06 Other Income 4.83 37.78 103.46 53.92 35.44 Total Revenues 98.60 291.63 498.32 911.53 492.82 Costs 77.91 300.49

Revenue From Operations 1,084.34 1,324.04 2,473.02 2,844.06 2,336.69 Other Income 4.17 7.95 14.89 15.70 17.83 Total Revenues 1,088.52 1,333.04 2,489.95 2,862.99 2,354.52 Costs 982.68 1,128.12 2,156.73

Other Income 5.10 2.71 22.98 28.81 37.82 Total Revenues 1,277.43 1,109.26 2,312.01 2,090.66 1,243.84 Costs 1,168.37 1,013.55 2,115.54 1,835.85 1,010.75 Selling And Administrative Expenses 54.20 43.67

have been issued. For the good corporate governance, the Board approved the cancellation of the approval to issue the ESOP warrants up to a total of 99,236,870 units to the Company’s directors and